Skip NavigationSkip to Content

Whole-body PET imaging of simian immunodeficiency virus using gp120-targeting probes fails to reveal regions of specific uptake in rhesus macaques

  1. Author:
    Srinivasula, Sharat
    Kim, Insook
    Jang, Hyukjin
    Degrange, Paula
    Brown, Heather
    Dalton, Viviana
    Badralmaa,Yunden
    Natarajan,Ven
    Long, Brad
    Carrasquillo, Jorge A
    Di Mascio, Michele [ORCID]
  2. Author Address

    AIDS Imaging Research Section, Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., AIDS Imaging Research Section, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., AIDS Imaging Research Section, Laulima Government Solutions, Integrated Research Facility, NIAID, NIH, Frederick, MD, USA., Laboratory of Molecular Cell Biology, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Molecular Imaging Program, Center for Cancer Research, NCI, NIH, Bethesda, MD, USA., AIDS Imaging Research Section, Division of Clinical Research, NIAID, NIH, Poolesville, MD, USA. mdimascio@niaid.nih.gov.,
    1. Year: 2025
    2. Date: Jan 31
    3. Epub Date: 2025 01 31
  1. Journal: European Journal of Nuclear Medicine and Molecular Imaging
  2. Type of Article: Article
  1. Abstract:

    Following the initial reports demonstrating the feasibility of immunoPET imaging of simian immunodeficiency virus (SIV) using gp120-targeting monoclonal antibodies in non-human primates, replication efforts of the imaging system in human immunodeficiency virus (HIV)-infected individuals have yielded conflicting results. Herein, we used two anti-gp120 antibodies, 7D3 and ITS103.01LS-F(ab')2, to interrogate the reproducibility of gp120-targeting probes for immunoPET imaging of SIV in rhesus macaques. The binding affinity estimates of 89Zr radiolabeled 7D3 and ITS103.01LS-F(ab')2 to SIV gp120, and the in-vitro and ex-vivo binding specificities of [89Zr]Zr-7D3 and [89Zr]Zr-ITS103.01LS-F(ab')2 to SIV Env expressing cells, primary cells, and tissue sections from uninfected and SIV-infected macaques were obtained through competition assays. The biodistributions of [89Zr]Zr-7D3 and [89Zr]Zr-ITS103.01LS-F(ab')2 were performed with static PET scans up to 6 days post-injection in 20 rhesus macaques and the standardized uptake values in various tissues were compared between SIV-infected and uninfected controls. Despite the demonstrated nanomolar affinity of [89Zr]Zr-7D3 and [89Zr]Zr-ITS103.01LS-F(ab')2 to SIV gp120, and strong binding specificity to SIV gp120 cell lines, we observed no discernible differences in their binding in primary cells, tissue sections of secondary lymphoid organs, in-vivo probe uptake between SIV-infected and uninfected macaques, or ex-vivo validation necropsies. While the probes remained stable in-vivo, only [89Zr]Zr-ITS103.01LS-F(ab')2 in chronic plasma retained its binding specificity to SIV gp120, with [89Zr]Zr-7D3 experiencing a?>?97% reduction in binding to gp120 due to competition from endogenous antibodies at the 7D3 binding site. The overall absence of specific uptake suggests inadequate binding potential (ligand affinity x target molarity) for these probes to effectively image SIV or HIV in-vivo, warranting further investigation into the lack of reproducibility observed with earlier non-human primate SIV imaging and conflicting human studies. © 2025. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.

    See More

External Sources

  1. DOI: 10.1007/s00259-025-07110-8
  2. PMID: 39888424
  3. PII : 10.1007/s00259-025-07110-8

Library Notes

  1. Fiscal Year: FY2024-2025
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel